FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...

Nine-ingredient formula featuring L-lysine, elderberry, and botanical extracts positions product among growing category of ...

Gilead will advance the clinical development and commercialization of the programs and Assembly Bio will receive a $35 ...

Get up to speed on herpes simplex virus (HSV-1/HSV-2) epidemiology, novel antibodies, vaccine development, and cure ...

A new study has confirmed genital herpes is the most common sexually transmitted infection (STI) in the world that does not have a cure and is lifelong. The burden on global health is immense.

Herpes simplex virus (HSV) is a common infection with two main types, HSV-1 and HSV-2, typically affecting the mouth or ...

Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.

Around 846 million people aged between 15 and 49 are living with genital herpes infections – more than 1 in 5 of this age-group globally – according to new estimates released today. At least 1 person ...

There are two types of herpes simplex virus (HSV). HSV-1 most commonly causes orolabial infection, while HSV-2 most commonly causes genital infection. HSV infection is very common, with 45%-98% of the ...

Scientists used a clinical-grade gum in experiments to "substantially" lower viral loads of two herpes simplex viruses and ...